New hope for colorectal cancer in nigeria: immunotherapy trial launches

NCT ID NCT06529523

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called tislelizumab for people in Nigeria with a specific type of colorectal cancer (mismatch repair deficient). The drug helps the immune system attack cancer cells. The study will check if the drug shrinks tumors and is safe. It includes 40 adults who have not had cancer treatment before.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Lagos University Teaching Hospital
NOT_YET_RECRUITING

Idi-Araba, Lagos, Nigeria

Contact Phone: •••-•••-••••
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

Contact Phone: •••-•••-••••
Obafemi Awolowo University Teaching Hospital
NOT_YET_RECRUITING

Ile-Ife, Nigeria

Contact Email: •••••@•••••